Venus Remedies share news and announcements
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,404.30down ₹37.20 (2.58%)BSE ₹1,396.30
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,441.50.
52-week range of traded prices to 23 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 26 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,877 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 16.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 2.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day.
- 52,800
Venus Remedies dividends
8 filed, newest first.
Jun 2014
3 Jun · Dividend
Board of Directors of the Company at its meeting held on May 30, 2014 has recommended a dividend @ 30% i.e. Rs 3/- per share for the financial year ended March 31, 2014 subject to approval of the same by shareholders at the Annual General Meeting.
May 2013
20 May · Dividend
Board of Directors of the Company at its meeting held on May 18, 2013 have recommended a dividend @ of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2013 subject to approval of the same by shareholders at the Annual General Meeting.
Jun 2012
21 Jun · Dividend
Board of Directors of the Company at its meeting held on June 21, 2012 have recommended a dividend of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2012 subject to approval of the same by shareholders at the Annual General Meeting.
Jul 2011
26 Jul · Dividend
Board of Directors of the Company at its meeting held on July 26, 2011, recommended a dividend @ of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2011 subject to approval of the same by shareholders at the Annual General Meeting.
Jul 2010
31 Jul · Dividend
Board of Directors of the Company at its meeting held on July 31, 2010, recommended a dividend @ of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2010 subject to approval of the same by shareholders at the Annual General Meeting.
Aug 2009
25 Aug · Dividend
Board of Directors at its meeting held on August 21, 2009 recommended a dividend @ of 30% i.e. Rs.3/- per share for the financial year ended March 31, 2009 subject to approval of the same by shareholders at the Annual General Meeting.
Jul 2008
29 Jul · Dividend
Board meeting held on July 29, 2008: (1) Approved enhancement of remuneration of working directors. (2) recommended a dividend @ of 40% for the financial year ended March 31, 2008 subject to approval of the same by shareholders at the Annual General Meeting. (3) Approved Change of Registered Office within the same city from S.C.O.39, Madhya Marg, Sector 26, Chandigarh to S.C.O. 857, Cabin No.10, 2nd Floor, N.A.C. Manimajra, Chandigarh-160101. (4) The Board also decided that Register of Members and Share Transfer Books shall remain closed from September 16, 2008 to September 22, 2008 (both days inclusive) for the purpose of Annual General Meeting and for the purpose of determining of entitlement to dividend.
Aug 2007
20 Aug · Dividend
August 20, 2007 that "The Board of Directors of Venus Remedies Limited at its meeting held today recommends a dividend @ of 30% for the financial year ended March 31, 2007 subject to the approval of the same by shareholders at the Annual General Meeting. The Board also decided that Register of Members and Share Transfer Books shall remain closed from 20th September 2007 to 24th September 2007 (both days inclusive) for the purpose of Annual General Meeting and for the purpose of determining of entitlement to dividend".